JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Johnson & Johnson is a stable company with a strong long-term outlook, but current technical indicators, insider selling trends, and short-term financial performance suggest it is not an optimal buy at this moment for a beginner investor with a long-term strategy. Holding or waiting for a better entry point is recommended.
The MACD histogram is negative and expanding, indicating bearish momentum. The RSI is at 28.235, suggesting the stock is approaching oversold territory but not yet providing a clear buy signal. Moving averages are converging, showing no strong trend. The stock is trading near its support level of 233.838, with resistance at 239.602.
Johnson & Johnson has raised its dividend for 64 consecutive years, indicating strong shareholder returns. The company is focusing on core segments of Innovative Medicine and MedTech, which are expected to drive future growth. Analysts highlight strong product pipelines and double-digit growth potential through the end of the decade.
The company's net income and EPS dropped significantly in Q1 2026, down -52.40% and -52.86% YoY, respectively.
In Q1 2026, revenue increased by 9.91% YoY to $24.06 billion, but net income dropped significantly by -52.40% YoY to $5.24 billion. EPS also declined by -52.86% YoY to $2.14. Gross margin remained stable at 66.46%.
Analysts have raised price targets, with most maintaining positive ratings. Morgan Stanley and RBC Capital are optimistic, citing strong product pipelines and growth potential. However, some firms like Barclays and Stifel remain neutral or cautious due to headwinds and recent financial performance.
